STOCK TITAN

[Form 4] Genelux Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Joseph Cappello, Chief Technical Officer of Genelux Corporation (GNLX), reported insider awards and holdings following transactions dated 08/27/2025. He was granted 107,500 restricted stock units (RSUs) that convert to one share each upon vesting and received a stock option covering 142,500 shares with an exercise price of $3.64 and an expiration date of 08/26/2035. After these transactions he beneficially owns 159,766 shares of common stock and 142,500 option shares. The RSUs vest 25% after one year and then in 12 equal quarterly installments; the option vests 25% after one year and then in 36 equal monthly installments.

Joseph Cappello, Chief Technical Officer di Genelux Corporation (GNLX), ha comunicato attribuzioni e posizioni di insider relative a operazioni datate 27/08/2025. Gli sono stati assegnati 107.500 unità azionarie vincolate (RSU), ciascuna convertibile in una azione al momento del vesting, e è stata concessa un’opzione su 142.500 azioni con prezzo di esercizio pari a $3,64 e scadenza il 26/08/2035. Dopo queste operazioni detiene beneficiariamente 159.766 azioni ordinarie e 142.500 azioni soggette a opzione. Le RSU maturano per il 25% dopo un anno e poi in 12 rate trimestrali uguali; l’opzione matura per il 25% dopo un anno e poi in 36 rate mensili uguali.

Joseph Cappello, Chief Technical Officer de Genelux Corporation (GNLX), notificó adjudicaciones y participaciones de insider tras operaciones fechadas el 27/08/2025. Se le otorgaron 107.500 unidades restringidas de acciones (RSU), convertibles en una acción cada una al vesting, y recibió una opción sobre 142.500 acciones con precio de ejercicio de $3,64 y fecha de vencimiento el 26/08/2035. Tras estas transacciones posee beneficiariamente 159.766 acciones ordinarias y 142.500 acciones en opción. Las RSU vencen en un 25% tras un año y luego en 12 cuotas trimestrales iguales; la opción vence en un 25% tras un año y luego en 36 cuotas mensuales iguales.

Genelux Corporation (GNLX) 최고기술책임자(CTO)인 Joseph Cappello는 2025-08-27자 거래에 따른 내부자 수령 및 보유를 보고했습니다. 그는 베스팅 시 각각 한 주로 전환되는 107,500개의 제한부 주식 단위(RSU)를 부여받았고, 행사가격 $3.64, 만료일 2035-08-26142,500주에 대한 스톡옵션도 받았습니다. 이 거래 후 그는 159,766주의 보통주142,500주의 옵션 주식을 실질적으로 보유하고 있습니다. RSU는 1년 후 25%가 베스트되고 이후 12회 분기별 동일 비율로 베스트되며, 옵션은 1년 후 25% 베스트된 뒤 36회 월별 동일 비율로 베스트됩니다.

Joseph Cappello, Chief Technical Officer de Genelux Corporation (GNLX), a déclaré des attributions et des avoirs d'initiés suite à des transactions datées du 27/08/2025. Il s'est vu attribuer 107 500 unités d'actions restreintes (RSU) convertibles chacune en une action lors du vesting, et a reçu une option sur 142 500 actions au prix d'exercice de 3,64 $ et expirant le 26/08/2035. Après ces opérations, il détient bénéficiairement 159 766 actions ordinaires et 142 500 actions en option. Les RSU acquièrent 25 % après un an puis le solde en 12 versements trimestriels égaux ; l'option acquiert 25 % après un an puis en 36 versements mensuels égaux.

Joseph Cappello, Chief Technical Officer von Genelux Corporation (GNLX), meldete Insider-Zuweisungen und -Bestände nach Transaktionen vom 27.08.2025. Ihm wurden 107.500 Restricted Stock Units (RSUs) gewährt, die jeweils bei Vesting in eine Aktie umgewandelt werden, und er erhielt eine Aktienoption über 142.500 Aktien mit einem Ausübungspreis von $3,64 und Ablaufdatum 26.08.2035. Nach diesen Transaktionen besitzt er wirtschaftlich 159.766 Stammaktien und 142.500 Optionsaktien. Die RSUs vesten zu 25% nach einem Jahr und danach in 12 gleichen vierteljährlichen Raten; die Option vestet zu 25% nach einem Jahr und dann in 36 gleichen monatlichen Raten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine executive equity awards align management incentives with shareholders without immediate dilution or cash proceeds.

The Form 4 shows standard equity compensation: RSUs and time-based stock options granted to the CTO on 08/27/2025. Vesting schedules (25% at one year then quarterly or monthly thereafter) are conventional and designed to retain the executive. The option exercise price of $3.64 sets a future incentive dependent on share-price appreciation. This filing is a common disclosure of insider compensation and does not indicate unusual governance concerns by itself.

TL;DR: Material only as insider ownership disclosure; no immediate cash flow impact and no exercised options reported.

The report records acquisition of 107,500 RSUs and grant of an option for 142,500 shares exercisable through 2035 at $3.64. Post-transaction beneficial ownership totals 159,766 common shares and 142,500 option shares. There is no sale or exercise reported, so no immediate dilution or proceeds. Investors should view this as management alignment rather than a liquidity event.

Joseph Cappello, Chief Technical Officer di Genelux Corporation (GNLX), ha comunicato attribuzioni e posizioni di insider relative a operazioni datate 27/08/2025. Gli sono stati assegnati 107.500 unità azionarie vincolate (RSU), ciascuna convertibile in una azione al momento del vesting, e è stata concessa un’opzione su 142.500 azioni con prezzo di esercizio pari a $3,64 e scadenza il 26/08/2035. Dopo queste operazioni detiene beneficiariamente 159.766 azioni ordinarie e 142.500 azioni soggette a opzione. Le RSU maturano per il 25% dopo un anno e poi in 12 rate trimestrali uguali; l’opzione matura per il 25% dopo un anno e poi in 36 rate mensili uguali.

Joseph Cappello, Chief Technical Officer de Genelux Corporation (GNLX), notificó adjudicaciones y participaciones de insider tras operaciones fechadas el 27/08/2025. Se le otorgaron 107.500 unidades restringidas de acciones (RSU), convertibles en una acción cada una al vesting, y recibió una opción sobre 142.500 acciones con precio de ejercicio de $3,64 y fecha de vencimiento el 26/08/2035. Tras estas transacciones posee beneficiariamente 159.766 acciones ordinarias y 142.500 acciones en opción. Las RSU vencen en un 25% tras un año y luego en 12 cuotas trimestrales iguales; la opción vence en un 25% tras un año y luego en 36 cuotas mensuales iguales.

Genelux Corporation (GNLX) 최고기술책임자(CTO)인 Joseph Cappello는 2025-08-27자 거래에 따른 내부자 수령 및 보유를 보고했습니다. 그는 베스팅 시 각각 한 주로 전환되는 107,500개의 제한부 주식 단위(RSU)를 부여받았고, 행사가격 $3.64, 만료일 2035-08-26142,500주에 대한 스톡옵션도 받았습니다. 이 거래 후 그는 159,766주의 보통주142,500주의 옵션 주식을 실질적으로 보유하고 있습니다. RSU는 1년 후 25%가 베스트되고 이후 12회 분기별 동일 비율로 베스트되며, 옵션은 1년 후 25% 베스트된 뒤 36회 월별 동일 비율로 베스트됩니다.

Joseph Cappello, Chief Technical Officer de Genelux Corporation (GNLX), a déclaré des attributions et des avoirs d'initiés suite à des transactions datées du 27/08/2025. Il s'est vu attribuer 107 500 unités d'actions restreintes (RSU) convertibles chacune en une action lors du vesting, et a reçu une option sur 142 500 actions au prix d'exercice de 3,64 $ et expirant le 26/08/2035. Après ces opérations, il détient bénéficiairement 159 766 actions ordinaires et 142 500 actions en option. Les RSU acquièrent 25 % après un an puis le solde en 12 versements trimestriels égaux ; l'option acquiert 25 % après un an puis en 36 versements mensuels égaux.

Joseph Cappello, Chief Technical Officer von Genelux Corporation (GNLX), meldete Insider-Zuweisungen und -Bestände nach Transaktionen vom 27.08.2025. Ihm wurden 107.500 Restricted Stock Units (RSUs) gewährt, die jeweils bei Vesting in eine Aktie umgewandelt werden, und er erhielt eine Aktienoption über 142.500 Aktien mit einem Ausübungspreis von $3,64 und Ablaufdatum 26.08.2035. Nach diesen Transaktionen besitzt er wirtschaftlich 159.766 Stammaktien und 142.500 Optionsaktien. Die RSUs vesten zu 25% nach einem Jahr und danach in 12 gleichen vierteljährlichen Raten; die Option vestet zu 25% nach einem Jahr und dann in 36 gleichen monatlichen Raten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cappello Joseph

(Last) (First) (Middle)
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD, SUITE 230

(Street)
WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 A(1) 107,500 A $0 159,766 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.64 08/27/2025 A 142,500 (2) 08/26/2035 Common stock 142,500 $0 142,500 D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.
2. The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.
/s/ Joseph Cappello 08/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Genelux Corp

NASDAQ:GNLX

GNLX Rankings

GNLX Latest News

GNLX Latest SEC Filings

GNLX Stock Data

125.79M
32.85M
11.4%
19.46%
5.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE